Reporting of Retrospective Registration in Clinical Trial Publications

Martin Haslberger* (MH), https://orcid.org/0000-0002-8067-2856, martin.haslberger@bih-charite.de

Stefanie Gestrich (SG), stefanie.gestrich@charite.de

Daniel Strech (DS), https://orcid.org/0000-0002-9153-079X, daniel.strech@bih-charite.de

Berlin Institute of Health at Charité – Universitätsmedizin Berlin, QUEST Center for Responsible Research, Charitéplatz 1, 10117 Berlin, Germany

* Corresponding author

Keywords: Clinical Trials, Trial Registration, Reporting, Retrospective Registration

Author Contributions
Martin Haslberger – Conceptualization, methodology, investigation, analysis, writing - original draft, project management
Stefanie Gestrich – Methodology, investigation
Daniel Strech – Conceptualization, methodology, supervision, writing – review and editing, funding acquisition

Open Data and Code
All code and the data for this study are available at https://github.com/mhaslberger/retrospective-registration.

Funding
This work was partly funded under a grant from the Federal Ministry of Education and Research of Germany (Bundesministerium fuer Bildung und Forschung - BMBF) [01PW18012]. The funder was not involved in the study design, data collection, analysis, or interpretation, writing of the manuscript, or the decision to submit for publication.

Conflicts
The authors declare no conflicts of interest.

Acknowledgments
We thank Maia Salholz-Hillel for conceptual feedback and technical support. We thank Martin R. Holst and Dr. Delwen Franzen for feedback on the manuscript.

Abstract

Objective: Prospective registration of clinical research has been widely implemented and advocated for many reasons: to detect and mitigate publication bias, selective reporting, and undisclosed changes in the determination of primary and secondary outcomes. Prospective registration allows for public scrutiny of trials, facilitates the identification of gaps in research, and supports the coordination of efforts by preventing unnecessary duplication. Retrospective registration undermines many of these reasons but is commonly found. We provide a comprehensive analysis of retrospective registration and the reporting thereof in publications, as well as factors associated with these practices.

Design: For this cross-sectional study, we used a validated dataset of trials registered on ClinicalTrials.gov or DRKS, with a German University Medical Center as the lead center, completed between 2009 and 2017, and with at least one peer-reviewed results publication. We extracted all registration statements from all results publications of retrospectively registered trials, including mentions and justifications of retrospective registration. We analyzed associations between key trial variables and different registration and reporting practices.

Results: In our dataset of 1927 trials with a corresponding results publication, 956 (53.7%) were retrospectively registered. Of those, 2.2% (21) explicitly report the retrospective registration in the abstract and 3.5% (33) in the full text. In 2.1% (20) of publications, authors provide a justification/explanation for the retrospective registration in the full text. Registration numbers were significantly underreported in abstracts of retrospectively registered trials (p < 0.001). Publications in ICMJE member journals had higher rates of both prospective registration and disclosure of retrospective registration, although not statistically significant. Publications in journals claiming to follow ICMJE recommendations showed lower rates compared to non-ICMJE-following journals.

Conclusions: In contrast to ICMJE guidance, retrospective registration is disclosed and explained only in a small number of retrospectively registered studies. Lack of disclosure might lead readers to wrongly interpret the registration as a quality criterion that, in the case of a retrospective registration, rather describes a concern. Disclosure of the retrospective nature of the registration would require 1-2 additional sentences in the manuscript and could be easily implemented by publishers.

Introduction

Prospective registration of clinical trials (i.e., registration before enrollment of the first participant) is an important practice to reduce biases in their conduct and reporting (1). A number of ethical and legal documents call for prospective registration: The Declaration of Helsinki (2) and the WHO registry standards (3) state that registration and results reporting of clinical trials are an ethical responsibility. In addition, many journals, via the International Committee of Medical Journal Editors (ICMJE), encourage or require prospective registration with an appropriate registry before the first participant is enrolled for all trials they publish, as well as the reporting of trial registration numbers in publications for better findability (4,5). Similarly, reporting guidelines such as CONSORT (6) and GPP3 (7) recommend the reporting of trial registration numbers.

Prospective registration has been widely implemented and advocated for many reasons: to detect and mitigate publication bias (i.e., the non-reporting of studies, or aspects of studies, that did not yield a positive result) and selective reporting (i.e., the selective reporting of only statistically significant primary outcomes). Prospective registration allows for public scrutiny of trials, identification of research gaps and to support the coordination of efforts by preventing unnecessary duplication (9). When trials are registered retrospectively, i.e., their registry entry is created after study start, this undermines the many of the reasons for registration. While prospective registration has increased over the past decade, retrospective registration is still widespread (10–14). Some registries, such as DRKS, explicitly mark retrospectively registered entries as such, whereas others, such as ClinicalTrials.gov, do not. While some publishers allow retrospectively registered trials to be published, others do not. Journals following ICMJE guidance should in principle mandate prospective registration, but this principle is not always enforced (12,15,16).

Our study aims to investigate the conduct of retrospective registration and its transparent reporting further. In a previous study in a cohort of 1509 trials conducted at German University Medical Centers, registered in DRKS or Clinicaltrials.gov, and reported as complete between 2009-2013, 75% were registered retrospectively (17). This rate dropped to 46% for the 1658 trials completed between 2014-2017 (18). Using the data from these two studies on trials registered in two large registries, led by German University Medical Centers, completed between 2009 and 2017, and with at least one available peer-reviewed results publication (17,18), we investigate whether and how authors report retrospective registration in the results publication. We also explore trends over time and how retrospective registration is associated with other practices such as reporting the trial registration number.

Methods

Data sources and sample. We based our sample on two related projects that were conducted at our research group (17,18). The projects have drawn a full sample (n = 3113) of registry entries for interventional studies reported as complete between 2009 and 2017, led by a German University Medical Center and registered in one of two registries: The ClinicalTrials.gov platform (CT.gov) and the Deutsches Register Klinischer Studien (DRKS), which is the WHO primary trial registry for Germany. Our dataset also includes the earliest results publications found for 68.4% (2129/3113) of the trials, which were manually identified in different stages until September 1st, 2020. We retrieved the combined data from the two projects from a GitHub repository (https://github.com/maia-sh/intovalue-data, accessed 22.02.2022).

Eligibility criteria. We included any trial that [1] was registered as an interventional study in either the ClinicalTrials.gov or the DRKS database, [2] was completed between 2009 and 2017, [3] reports a

German University Medical Center (UMC) listed as the responsible party or lead sponsor, or with a
principal investigator from a German UMC, [4] has published results in a peer-reviewed journal.
Detailed descriptions of how these variables were derived are provided in the original publications of
the dataset (17,18). Retrospective registration was determined based on the registration and study
start dates in the registry entries: dates were set to the first of the respective month and studies
with a registration date more than one month after start date counted as retrospectively registered.
Data extraction. For all retrospectively registered trials, we manually searched the abstract and the
full text of the publications, including editorial statements, whether they reported
- the fact that the study was registered (binary),
- a trial registration number (binary),
- the exact wording used to report the registration, including any provided registration numbers (free text),
- the date of the retrospective registration (binary), and
- the fact that the study was retrospectively registered (binary).
- We also assessed whether (binary) and how authors justified or explained the retrospective registration (free text).

One rater (MH) used the keywords "regist", "nct", "drks", "eudra", "retro", "delay", and "after" to
search for registration numbers and wording pointing to retrospective registration in all publications.
We considered a retrospective registration statement transparent if the authors explicitly mentioned
that the registration was retrospective, e.g., "this study was retrospectively registered in [registry],
[TRN]". Reporting of the registration date alone was not considered as transparent reporting of
retrospective registration, except if the date of registration was mentioned in combination with the
study start date in the same paragraph.
ICMJE journals. We created additional variables for whether journals follow the ICMJE
recommendations (list available on http://www.icmje.org/journals-following-the-icmje-
recommendations/, accessed 07.04.2022).
Cross-registrations. We classified all retrospectively registered studies in our sample that report a
registration in EudraCT in the publication as prospective, as registrations on the platform are
required prior to the approval of regulatory agencies or research ethics committees (19).
Reliability assessment of ratings. To assess the reliability of the data extraction, another rater (SG)
performed three validation steps: first, a sample of 100 publications was screened using the same
extraction form, during the main screening to refine category definitions. Second, another sample of
100 publications for which no registration number reporting was noted by MH to check for false
negative ratings. Third, all cases with either date, or reporting of retrospective registration or
justification were screened, to check for false positives.
Analyses
Associations between prospective registration and other variables
To test the strength of the associations between prospective registration and three variables, we
used Pearson's chi-squared independence test or Fisher's exact test (for small numbers). These
variables are (1) publication in a ICMJE member journal or a journal following ICMJE
recommendations, (2) reporting of a registration number, and (3) industry funding.
Associations between reporting of retrospective registration and other variables
To test the strength of the associations between the reporting of retrospective registration and two
binary variables, we used Fisher's exact test. These variables are (1) publication in a ICMJE member
journal or a journal following ICMJE recommendations, and (2) industry funding.

Software

We used Microsoft Excel for data collection and R (version 4.0.3) for data analysis and visualization.

Reporting

We checked our manuscript against the STROBE checklist (supplementary Table 1) (20).

Results

Sample of retrospectively registered trials. After applying the above-mentioned exclusion criteria,

1927 (1932 - 5) registered studies with an associated results publication remained. Of these, 1038

(53.7%) were retrospectively registered according to the information provided in Clinicaltrials.gov

and DRKS. We screened these 1038 studies for our analysis. 77 (7.8%) of the publications provided a

EudraCT number, in which case we reclassified the study as prospectively registered. For statistical

comparisons, we used the prospectively registered studies in the dataset as a control group. A

flowchart of this study selection is provided in Figure 1. Basic characteristics of included trials are

available in supplementary Table 2.

Figure 1: Flowchart of in-/exclusion of studies. From the 1038 trials that were retrospectively registered in Clincialtrials.gov

or DRKS, we excluded 5 publications that clearly did not report clinical study results (e.g., secondary analyses of CT data)

and another 77 that reported EudraCT entries in the publications, resulting in 956 retrospectively registered studies from a

total dataset of 1927 (971 + 956) studies.

Retrospective registration. Figure 2 shows the extent of retrospective registration over time, which

has been falling steadily from 100% in 2004 to 25% in 2017.

Figure 2: Percentage of retrospectively registered (RR) trials over time (per <u>study start year</u>). GAM (generalized additive model) smoother laid over (blue). Bubble sizes indicate the number of trials per year in the dataset.

We describe associations between prospective registration and previously defined binary variables in Table 1: We found no statistically significant association between publications in ICMJE member journals and prospective registration. Trials published in journals reporting to follow ICMJE recommendations were even prospectively registered at a lower rate, compared to non-following journals. It is important to note here that the information on ICMJE-following is based on journals' requests to be included on the ICMJE website, therefore our results suggest that journals requesting to be featured on the site often do not enforce the recommendations strongly. However, there are other journals, such as many PloS journals, that are not featured on the ICMJE site, but implement the recommendations. Retrospectively registered trials, compared to prospectively registered trials significantly underreported registration numbers in the abstract (p = 0.0007). Industry sponsorship of trials was associated with prospective registration (p = 0.002).

Table 1: Associations between prospective registration and other variables

Variable		# (%) prospectively registered	P-value
ICMJE member journal	Y	28 (63.6%)	p = 0.09 (Fisher)
	N	943 (50.1%)	
ICMJE member/following journal	Y	329 (49.2%)	p = 0.47 (Chi-sq.)
	N	642 (51.0%)	
TRN reporting in abstract	Y	404 (55.4%)	p = 0.0007*** (Chi-sq.)
	N	567 (47.3%)	
Industry sponsorship	Y	163 (59.3%)	p = 0.002** (Chi-sq.)
	N	808 (48.9%)	

Reporting of registration. In 783 (81.9%) of the remaining 956 results publications of retrospectively registered trials, the registration was explicitly reported in either the abstract or the full text. In all

205 except four of these publications, the registration was mentioned by providing the registration
206 number. In the other cases, the registration was mentioned but without reporting a registration
207 number.
208
209 *Table 2: Number of retrospectively registered trials and prevalence of key retrospective registration reporting practices.*
210 ** "other" includes footnotes, sidebars, etc.*

	n	% (of total)
Total: Retrospectively registered trials	**956**	**100.0%**
Registration reported	783	81.9%
Registration number reported	**779**	**81.5%**
in abstract	*325*	*34.0%*
in full-text	*535*	*56.0%*
in other*	*134*	*14.0%*
Registration date reported	**67**	**7.0%**
in abstract	*45*	*4.7%*
in full-text	*32*	*3.3%*
Retrospective registration addressed	**47**	**4.9%**
in abstract	*21*	*2.2%*
in full-text	*33*	*3.5%*
Retrospective registration justified/explained	**20**	**2.1%**
in abstract	*0*	*0.0%*
in full-text	*20*	*2.1%*

211
Reporting of retrospective registration. The rate of trials for which retrospective registration is
reported transparently increased over the last years up to 15.4% in 2020 (Figure 3). Overall, among
all 956 retrospectively registered clinical studies, only 47 (4.9%) mention explicitly that this
registration was retrospective in the abstract or full text. Among those cases, 20 give some
explanation or justification for why registration was retrospective; we provide examples for these
cases below in Table 2. In 67 (7.0%) cases, the authors reported the registration date alongside the
registration statement, but in 35 of those, the date was provided without giving the necessary
context that the registration was retrospective.
220

Year (Pub.)	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
n	2	0	2	12	40	111	144	199	205	240	278	234	215	160	85
RRR	0	0	0	0	0	0	0	1	0	5	12	9	10	4	6
% RRR	0		0	0	0	0	0	0.9	0	4.4	8.5	8.7	11.2	8	15.4

221
Figure 3: Percentage of retrospectively registered trials reporting retrospective registration transparently in the publication
over time (per <u>study publication year</u>). GAM (generalized additive model) smoother laid over (blue). Bubble sizes indicate
the number of trials per year in the dataset. Starting in 2013, some authors begin to report retrospective registration. 15%
of publications of retrospectively registered trials from 2020 transparently report retrospective registration. Four trials were
published before 2009 – in all those cases the study completion dates provided in the registry were after 2009. Study start
dates were before 2005 and studies were registered in 2005 (3/4) or later (1/4).

228
229 Publications in ICMJE member or -following journals had a higher rate of reporting of retrospective
230 registration (p = 0.004) but we found no association for industry sponsored trials (p = 0.162) (Table
231 3).

232
233 *Table 3: Associations between transparent reporting of retrospective registration and other variables*

Variable		# (%) reporting RR	P-value
ICMJE member journal	Y	2 (12.5%)	p = 0.184 (Fisher exact)
	N	45 (4.8%)	
ICMJE member/following journal	Y	7 (2.1%)	p = 0.004** (Fisher exact)
	N	40 (6.5%)	
Industry sponsorship	Y	2 (1.8%)	p = 0.162 (Fisher exact)
	N	45 (5.3%)	

234
235 *Justifications of retrospective registration.* In 24 cases in which the retrospective nature of the
236 registration was reported, the authors provided further information explaining or justifying the
237 retrospective registration. Table 2 shows the main themes present in authors' explanations, with
238 text examples.

239
240 *Table 4. Main themes identified from authors' explanations of retrospective reporting and example statements.*

Theme	Example(s)
Unawareness of policy	"At the time when the trial was started, the initiators of this study were unfortunately unaware of the policy of the International Committee of Medical Journal Editors (ICMJE), which requires prospective registration of all interventional clinical trials. As soon as we became aware of this policy, we registered the trial." (PMID: 26812052)

	"The reason for retrospectively registering the study was that the study authors were not aware of the recommendation to register diagnostic accuracy studies before this date." (PMID: 30011285)
Registry delays	"Registration of the study was applied for in April 2015. All queries from the DRKS were answered until the 31st August 2015 except the planned inclusion date of the first patient (first-patient-in), which was correct in the DRKS registry on 1st December 2015. Confirmation of registration occurred on 4th December 2015. The first patient was recruited and randomized into the study on 20th October 2015. Until 4th December 2015 eight patients were randomized into the trial." (PMID: 32142529)
Not obligatory at the time	"At the time of submission of the study protocol, the Ethics Committee did not require registration for feasibility or proof of concept studies. The study was registered in ClinicalTrials.gov (NCT02196545) in July 2014 in preparation of a manuscript for publication of the data. The authors confirm that all ongoing and related trials for this intervention are registered." (PMID: 25884637)
	„It was not registered at a clinical trial register, because at the time of setup in 2003, such a registration was not obligatory." (PMID: 23730377)
Not obligatory for the intervention	"According to national laws it is stipulated to inform the respective ethics committee, but it was not necessary to register the study in an official registry or to obtain an ethics committee vote, because it was an expanded access study (Heilversuch). Despite this, we prospectively obtained a vote of the ethics committee. Study design and patient information form were approved by the local ethics committee (ethics committee of the regional medical association; approval no. EK-BR-50/10-1, date of approval December 10th, 2010). In addition, the study was registered at www.clinicaltrials.gov (ID no. NCT02168790)." (PMID: 25955359)
Miscommunnication between investigators	"The time of first registration was June 17, 2013, and final approved trial registration was July 1, 2013. First patient inclusion was in July 2012 at the Heart Center Leipzig University Hospital, Leipzig, Germany. Thus, there was a delay between first patient inclusion and trial registration that was the result of a misunderstanding between the principal investigator of the trial, Dr Thiele, and the first author, Dr Fuernau, who was responsible for clinical project coordination at the investigator's site at the Heart Center Leipzig University of Leipzig. According to initial communication, registration had to be performed by Dr Fuernau. When the study principal investigator recognized that it had not been performed, we immediately registered the trial at http://www.ClinicalTrials.gov. At this time, only 7 patients at the Heart Center Leipzig University Hospital had been included in the trial." (PMID: 30026282)
	„[…] there was a delay of trial registration before first patient inclusion which was induced by a misunderstanding between the project coordination for the EU grant (at this time gabo:mi, later on ARTTIC) and the clinical project coordination at the investigator's site at the Heart Center Leipzig - University of Leipzig. According to initial communication registration should be performed by gabo:mi. When the study coordinator recognized that it has not been performed we immediately registered it at clinicaltrials.gov. At this time only 13 patients at the Heart Center Leipzig University Hospital (and no other study site) have been included into the trial." (PMID: 29083953)
Publication	"Registration was done after the study has been conducted and the results suggested a publication and further continuation of this research." (PMID: 27485732)
Confidentiality	"The principal investigator (N.H.) delayed the registration of the study until data acquisition was completed for confidentiality reasons concerning the study methods, especially the magnetic resonance with the related morphometric measurements." (PMID: 26305790)
Logistic/ Administrative issues	"Because of administrative problems, release of registration occurred about six months after study start. The authors confirm that all ongoing and related trials for this intervention are registered. Relevant de-identified data can be downloaded from https://osf.io/426pd." (PMID: 31465443)
	"Due to organisational changes in the research project shortly before the start of the recruitment we put great efforts into avoiding a delayed start of the data collection in the cooperating inpatient units, which resulted in retrospective study registration and a delayed publication of our study protocol." (PMID: 29077724)
	„Registration of the trial was delayed after the enrollment of the first patient due to an administrative error. The authors confirm that all ongoing and related trials for this intervention are registered." (PMID: 26501562)

Discussion

In this study we show that in a sample of 956 results publications from retrospectively registered

clinical studies led by German UMCs and completed between 2009 and 2017, only a small number of

publications (4.9%) make the retrospective nature of the registration transparent, and even fewer

(2.1%) explain the reasons for retrospective registration. To our knowledge, only two studies have

previously addressed the reporting of retrospective registration: Al-Durra et al. (21) found in a

sample of 286 publications in ICMJE member journals and published in 2018 that only 2.8% (n=8) of

papers of retrospectively registered trials in their sample include justifications or explanations for

delayed registration. Loder et al. (22), in their analysis of 70 papers submitted to the BMJ from 2012-

2015 and rejected for registration issues, found that 2.9% (n=2) disclosed the registration problem

when published in another journal. Our study finds a slightly lower percentage of 2.1% for

explanations of the reasons for retrospective registration, but a higher percentage of 4.9% for

disclosure in a larger sample representing a more diverse selection of journals and broader time
frame.
There were diverse reasons for retrospective registration brought forth by authors, many of which
have been published previously (21,22). In some cases, authors raise points that lie outside their
direct responsibility, such as delays caused by the registry or research not being legally required to
be preregistered. Several other reasons provided were within authors' control, such as logistic and
administrative issues, miscommunication between researchers or unawareness of registration
policies. In some cases, authors report registering a study to meet journal editorial policies even
though registration would not be required for the kind of research otherwise. Another identified
theme revolves around the confidentiality of methods – however, in this case many other data
about the trial could have been preregistered.
266
Limitations
For feasibility and data quality reasons, our study was based on an existing validated dataset,
containing only trials led by German UMCs, which might limit its generalizability to other regions. For
example, in Germany, unlike many other countries, there is no legal mandate to register all clinical
studies, but the largest funding institutions in Germany (e.g., DFG, BMBF) require the registration of
studies as prerequisite for funding. However, the sample also contained multi-center trials with
other countries involved and is much larger and from a wider variety of journals than in previous
studies (21,22). In addition, due to Germany's high research output (23) our results in any case
highlight a key transparency issue in a major research environment.
Our analysis of retrospective registration is based on trial start dates and registration dates as
provided by the two registries used for sampling: Clinicaltrials.gov and DRKS. It is possible that
authors did not update their registry entries when delays to the start date occurred. For example,
we did not specifically follow up cases in which authors wrote that a trial was registered
prospectively, but the registry dates did not reflect that statement. In our analyses involving the
classification into ICMJE-following and non-following journals, we relied on the data provided on the
ICMJE website (icmje.org), which are self-reported by journals, i.e., a journal must write to the ICMJE
that they want to be included in the list. Thus, there are some journals missing in the ICMJE data and
therefore in our dataset. For ICMJE member journals (n=16) on the other hand, there is a complete
listing available.
286
Conclusion
The Declaration of Helsinki and many other guidelines for responsible clinical research unanimously
recommend prospective registration of all clinical studies. For highly regulated clinical trials this was
even codified into law. A major aim of prospective registration is to minimize the risk of undisclosed
changes in the protocol after the study started and first results are analyzed. When registration
happens retrospectively, this major goal is not addressed. The reporting of study registration is
generally considered a best practice to make a study more trustworthy. In the case of retrospective
registration, in contrast, reporting registration without transparency on the retrospective nature
should rather raise concerns as readers might wrongly interpret the mentioning of registration as a
quality criterion. This could be considered "performative reproducibility", i.e., the "pretence of
reproducibility without the reality" (24). Journals could enforce explicit reporting and explanation of
retrospective registration, but we found that this rarely happens. A simple note in the registration

statement of the paper would suffice, such as: "This study was retrospectively registered at

[Registry], [X] days after the trial started because [Reason]".

References

1.	Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986 Oct;4(10):1529–41.

2.	WMA. World Medical Association: Declaration of Helsinki - Ethical Principles for Medical Research involving Human Subjects [Internet]. 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

3.	World Health Organization. International standards for clinical trial registries: the registration of all interventional trials is a scientific, ethical and moral responsibility [Internet]. version 3.0. Geneva: World Health Organization; 2018 [cited 2022 Feb 1]. 48 p. Available from: https://apps.who.int/iris/handle/10665/274994

4.	ICMJE. International Committee of Medical Journal Editors Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals [Internet]. [cited 2021 Oct 18]. Available from: http://www.icmje.org/icmje-recommendations.pdf

5.	De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet Lond Engl. 2004 Sep 11;364(9438):911–2.

6.	Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340(mar23 1):c869–c869.

7.	Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015 Sep 15;163(6):461–4.

8.	Food and Drug Administration. Food and Drug Administration Amendments Act of 2007 [Internet]. 110-85 Sep 27, 2007. Available from: https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf

9.	Zarin DA, Keselman A. Registering a Clinical Trial in ClinicalTrials.gov. Chest. 2007 Mar;131(3):909–12.

10.	Trinquart L, Dunn AG, Bourgeois FT. Registration of published randomized trials: a systematic review and meta-analysis. BMC Med. 2018 Oct 16;16(1):173.

11.	Birajdar AR, Bose D, Nishandar TB, Shende AA, Thatte UM, Gogtay NJ. An audit of studies registered retrospectively with the Clinical Trials Registry of India: A one year analysis. Perspect Clin Res. 2019 Mar;10(1):26–30.

12.	Scott A, Rucklidge JJ, Mulder RT. Is Mandatory Prospective Trial Registration Working to Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An Observational Study of Five Psychiatry Journals That Mandate Prospective Clinical Trial Registration. Wicherts JM, editor. PLOS ONE. 2015 Aug 19;10(8):e0133718.

13.	Mann E, Nguyen N, Fleischer S, Meyer G. Compliance with trial registration in five core journals of clinical geriatrics: a survey of original publications on randomised controlled trials from 2008 to 2012. Age Ageing. 2014 Nov;43(6):872–6.

14.   Smaïl-Faugeron V, Fron-Chabouis H, Durieux P. Clinical trial registration in oral health
journals. J Dent Res. 2015 Mar;94(3 Suppl):8S-13S.

15.   Harriman SL, Patel J. When are clinical trials registered? An analysis of prospective versus
retrospective registration. Trials. 2016 Apr 15;17:187.

16.   Boughton S. Retrospectively registered trials: the Editors' dilemma [Internet]. Research in
progress blog. 2016 [cited 2022 Jul 21]. Available from:
https://blogs.biomedcentral.com/bmcblog/2016/04/15/retrospectively-registered-trials-editors-
dilemma/

17.   Wieschowski S, Riedel N, Wollmann K, Kahrass H, Müller-Ohlraun S, Schürmann C, et al.
Result dissemination from clinical trials conducted at German university medical centers was
delayed and incomplete. J Clin Epidemiol. 2019 Nov;115:37–45.

18.   Riedel N, Wieschowski S, Bruckner T, Holst MR, Kahrass H, Nury E, et al. Results
dissemination from completed clinical trials conducted at German university medical centers
remained delayed and incomplete. The 2014 –2017 cohort. J Clin Epidemiol. 2022 Apr;144:1–7.

19.   European Medicines Agency. Regulation (EU) No 536/2014 of the European Parliament and
of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing
Directive 2001/20/EC [Internet]. Jan 31, 2022. Available from:
http://data.europa.eu/eli/reg/2014/536/2022-01-31

20.   von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
guidelines for reporting observational studies. Lancet Lond Engl. 2007 Oct 20;370(9596):1453–7.

21.   Al-Durra M, Nolan RP, Seto E, Cafazzo JA. Prospective registration and reporting of trial
number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and
Declaration of Helsinki recommendations. BMJ. 2020 Apr 14;m982.

22.   Loder E, Loder S, Cook S. Characteristics and publication fate of unregistered and
retrospectively registered clinical trials submitted to The BMJ over 4 years. BMJ Open. 2018 Feb
16;8(2):e020037.

23.   German science on the world stage: visualized. Nature. 2020 Nov 26;587(7835):S110–1.

24.   Buck S. Beware performative reproducibility. Nature. 2021 Jul 8;595(7866):151–151.

371